Oncology From promise to practice: What must happen next for genetic ... The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.
News 23andMe study explains variable results with obesity drugs Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
Patients Sponsored Why rare kidney diseases must be part of the CKD conversatio... A look at the benefits of genetic testing in diagnosis of rare kidney diseases, from HealthLumen.
News 23andMe fined £2.31m over UK users' genetic data breach Genetic testing company 23andMe is facing a hefty fine from the UK's data protection watchdog for failing to protect its customers' data.
News Former CEO wins bidding war for 23andMe, beating Regeneron 23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the genetic testing business.
News New auction for 23andMe sought with $305m bid from ex-CEO A new auction for bankrupt genetic testing company 23andMe looks likely after former CEO Anne Wojcicki offered to outbid Regeneron.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.